


ANSWER 27 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2002:615461 CAPLUS  
 DOCUMENT NUMBER: 137:169502  
 TITLE: Preparation and antiviral activity for HIV-1 of substituted azaindoleoxoacetylpiperazines  
 INVENTOR(S): Wang, Tao; Zhang, Zhongxing; Meanwell, Nicholas A.; Kadow, John F.; Yin, Zhiwei  
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA  
 SOURCE: PCT Int. Appl., 367 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002062423	A1	20020815	WO 2002-US455	20020102
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2437524	AA	20020815	CA 2002-2437524	20020102
EP 1363705	A1	20031126	EP 2002-707413	20020102
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300359	A	20031215	EE 2003-359	20020102
BR 2002006636	A	20040225	BR 2002-6636	20020102
NZ 527193	A	20040528	NZ 2002-527193	20020102
JP 2004522755	T2	20040729	JP 2002-562428	20020102
CN 1612763	A	20050504	CN 2002-807826	20020102
BG 108021	A	20040430	BG 2003-108021	20030722
ZA 2003005885	A	20041101	ZA 2003-5885	20030730
NO 2003003436	A	20031001	NO 2003-3436	20030801
PRIORITY APPLN. INFO.:			US 2001-266183P	P 20010202
			US 2001-314406P	P 20010823
			WO 2002-US455	W 20020102
OTHER SOURCE(S):			MARPAT 137:169502	
GI				



I

AB Title compds. Q(CO)nWCOA [Q = (un)substituted azaindolyl; W = (un)substituted piperazino; A = (un)substituted alkoxy, aryl, heteroaryl;

n = 1, 2] were prepared for use as antiviral agents, alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors, in the treatment of HIV and AIDS. Thus, 2-chloro-3-nitropyridine was cyclized with vinylmagnesium bromide to give 7-chloro-6-azaindole which was treated with ClCOCO2Me, followed by ester hydrolysis, amidation with (R)-3-methyl-1-benzoylpiperazine, and substitution with 4-FC6H4B(OH)2 to give the title compound I which had an EC50 for HIV-1 in vitro of <1  $\mu$ M.

IT 446289-04-9P 446290-82-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and antiviral activity for HIV-1 of substituted azaindoleoxoacetyl piperazines)

RN 446289-04-9 CAPLUS

CN Piperazine, 4-benzoyl-1-[[5-chloro-7-(5-oxazolyl)-1H-pyrrolo[3,2-b]pyridin-3-yl]oxoacetyl]-2-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 446290-82-0 CAPLUS

CN Piperazine, 4-benzoyl-2-methyl-1-[oxo[7-(2-thienylcarbonyl)-1H-pyrrolo[3,2-b]pyridin-3-yl]acetyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT